Achaogen Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
13,112.00
20,176.00
27,093.00
71,227.00
125,618.00
Depreciation, Depletion & Amortization
506.00
358.00
426.00
441.00
1,334.00
Other Funds
1,928.00
2,558.00
3,804.00
24,751.00
12,918.00
Funds from Operations
10,678.00
17,260.00
22,863.00
46,035.00
111,366.00
Changes in Working Capital
3,176.00
2,977.00
1,775.00
868.00
16,111.00
Net Operating Cash Flow
13,854.00
14,283.00
21,088.00
46,903.00
95,255.00
Capital Expenditures
110.00
340.00
606.00
901.00
7,106.00
Purchase/Sale of Investments
-
45,087.00
5,838.00
11,269.00
7,574.00
Net Investing Cash Flow
110.00
45,427.00
5,232.00
10,368.00
468.00
Issuance/Reduction of Debt, Net
4,632.00
6,896.00
14,590.00
10,000.00
4,167.00
Net Financing Cash Flow
17,629.00
67,853.00
17,262.00
135,462.00
130,411.00
Net Change in Cash
3,665.00
8,143.00
1,406.00
98,927.00
35,624.00
Free Cash Flow
13,964.00
14,623.00
21,694.00
47,804.00
102,361.00
Change in Capital Stock
22,261.00
74,749.00
2,672.00
125,462.00
134,578.00

About Achaogen

View Profile
Address
1 Tower Place
South San Francisco California 94080
United States
Employees -
Website http://www.achaogen.com
Updated 09/14/2018
Achaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections. It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae. The company was founded by Nathaniel E.